

**Table 1: Potential treatment approaches against novel corona virus 19 (SARS-Cov-2)**

<b>Approaches</b>	<b>Drug name</b>	<b>Country of origin (References)</b>
Inhibition of SARS-CoV-2 fusion/entry	<i>SARS-CoV CR3022</i>	China, (23)
	<i>Camostat mesylate</i>	Germany, (24)
	<i>Modified OC43-HR2P peptide</i>	China, (25)
	<i>Baricitinib</i>	UK, (26)
	<i>Chloroquine phosphate, Hydroxychloroquine</i>	China (27), (28)
Disruption of SARS-CoV-2 replication	<i>Remdesivir, favipiravir and ribavirin</i>	China, USA, Belgium (29-31)
	<i>Prulifloxacin, Tegobuvir, Bictegravir and Nelfinavir</i>	USA, China (32), (33)
Suppression of excessive inflammatory response	<i>Corticosteroids</i>	China, (34)
	<i>Tocilizumab</i>	Genetech (Roche), USA
Convalescent plasma treatment		National Health Commission (NHC), China
Vaccines	<b>Company name</b>	
	<i>Moderna Therapeutics</i>	USA (35)
	<i>Stermirna Therapeutics</i>	China (36)
	<i>CureVac</i>	Germany (37)
	<i>Inovio Pharmaceuticals</i>	USA (35), (38)
	<i>Novavax</i>	USA (35)
	<i>Vir Biotechnology</i>	USA (39), (40)
	<i>Hong Kong University</i>	Hong Kong (41)